Top Story Today
A 14-Day Infusion That Rewrites the Rules of Childhood Type 1 Diabetes
The FDA approved Tzield (teplizumab) as the first drug that actually slows the autoimmune attack behind childhood type 1 diabetes, rather than simply replacing lost insulin. In the pivotal PROTECT trial, 94.9% of kids on Tzield maintained meaningful insulin production at 78 weeks versus 79.2% on placebo. It's not a cure; these children still need insulin. But it reframes a century-old metabolic problem as an interceptable autoimmune disease, opening an entirely new treatment category for the 18,000 American kids diagnosed each year.
Why it matters: This approval transforms pediatric T1D from a manage-the-symptoms disease into one that can be actively modified at the immune level. If you can intercept the autoimmune destruction early, population-level screening programs suddenly have a therapeutic payoff, and an entirely new franchise category emerges.
Read more →Clinical Wins and Losses
Pfizer's First New Drug From Its $43B Seagen Deal Just Failed Phase 3
Pfizer's sigvotatug vedotin, a guided-missile ADC targeting integrin b6, failed to extend survival versus old-school chemo in 703 lung cancer patients. The company is pointing to a subgroup with "stronger trends" but hasn't released actual numbers. One trial doesn't sink a 12-ADC pipeline, but it raises uncomfortable questions about whether the biggest pharma deal in years can deliver on its growth promises.
Read more →Merck's $10.8B Gut Health Gamble Clears Its Biggest Hurdle
Tulisokibart just became the first anti-TL1A antibody to hit its primary endpoint in a Phase 3 ulcerative colitis trial. The drug blocks both inflammation and fibrotic scarring, a dual mechanism no current IBD therapy offers. Analysts project $5.2 billion in peak sales, and Merck is eyeing a 2027 launch as it races to build life after Keytruda.
Read more →Exelixis' Cabometyx Successor Scores 89 on a Test Where 90 Is Passing
Zanzalintinib missed its co-primary survival endpoint in colorectal cancer patients without liver metastases (p=0.1185), sending Exelixis shares down 10-12%. The drug did meet its other primary endpoint in the full population, and an FDA decision on the broader filing is due December 3. But for a company that gets more than 80% of revenue from one aging drug, the miss stings.
Read more →Regulatory Shakeups
The FDA Is Now Watching Clinical Trials in Real Time
Two live proof-of-concept trials with AstraZeneca and Amgen are streaming pre-specified safety signals directly to FDA reviewers as they happen, ditching the old batch-submission model. Analysts estimate the approach could cut oncology review timelines by 20-30%. A broader pilot launches this summer, but smaller biotechs worry the rules will be written without them at the table.
Read more →HHS Admits Companies Were Doing Months of Homework Nobody Assigned
Operation TrialBlazer aims to cut 6-12 months off Phase 1 timelines by clarifying that sponsors have been submitting manufacturing data the FDA never actually required. For early-stage biotechs burning $1-2 million per month, that's the difference between reaching proof-of-concept and running out of cash. A new expedited IND pilot and regulatory navigator launch this summer.
Read more →A 77% Response Rate Earns Merck's KRAS Combo a Fast Pass
The FDA granted Breakthrough Therapy designation to calderasib plus Keytruda for first-line KRAS G12C lung cancer after a Phase 1 trial showed a high response rate, roughly double what Keytruda achieves alone. Two Phase 3 trials are running, with the first readout expected within a couple years. After four decades of being "undruggable," KRAS keeps getting drugged.
Read more →Drug Delivery and New Modalities
Cancer Treatment Just Got a Wearable Device
The UK approved the first cancer drug delivered via an on-body injector: Sanofi's Sarclisa for multiple myeloma, administered in 13 minutes at home instead of hours in an infusion center. The FDA decision for the U.S. is due July 23. Home infusion costs significantly less than hospital-based delivery, and once patients taste the convenience, going back is nearly impossible.
Read more →Regeneron's Quarterly Shot for Myasthenia Gravis Gets Priority Review
Cemdisiran, an RNA-based drug that teaches the liver to stop making a problematic immune protein, earned FDA Priority Review for generalized myasthenia gravis. One subcutaneous shot every three months produced clinically meaningful improvement in 77% of patients in Phase 3. The decision date is November 2026, and it would be the first siRNA therapy approved for the condition.
Read more →An AI-Designed Drug Just Crossed Into the Human Brain
Insilico Medicine dosed the first human volunteer with ISM8969, a generative-AI-designed molecule that crosses the blood-brain barrier to target Parkinson's-related inflammation. Most drugs (roughly 98%) can't breach that barrier. The Phase 1 trial will collect spinal fluid samples to confirm brain penetration; if positive, it validates AI drug design for the hardest organ to treat.
Read more →